Learn More
PURPOSE We have previously reported that matrix metalloproteinases MMP-2, MMP-9, and the complex MMP-9/NGAL can be detected in urine of patients with a variety of cancers including prostate and bladder carcinoma. In addition, we also detected several unidentified urinary gelatinase activities with molecular weights >125 kDa. The objective of the current(More)
The objective of this study was to discover and to validate novel noninvasive biomarkers that distinguish between benign prostate hyperplasia (BPH) and localized prostate cancer (PCa), thereby helping to solve the diagnostic dilemma confronting clinicians who treat these patients. Quantitative iTRAQ LC/LC/MS/MS analysis was used to identify proteins that(More)
Tissue inhibitors of metalloproteinases (TIMPs), the endogenous inhibitors of matrix metalloproteinases, have been shown to possess biological functions that are independent of their ability to inhibit matrix metalloproteinases. We have previously shown that the C-terminal domain of TIMP-2 and, in particular, Loop 6 inhibit capillary endothelial cell(More)
iv ACKNOWLEDGMENTS I would like to thank all those people whose contributions have made this work possible. Dr. Diane Bielenberg, thank you for being an amazing research mentor. Your support, wisdom, feedback and professional advice has been a blessing. I would also like to thank Dr. Hironao Nakayama and Dr. Roopali Roy for their assistance in(More)
  • 1